[go: up one dir, main page]

BR9909328A - Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf - Google Patents

Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf

Info

Publication number
BR9909328A
BR9909328A BR9909328-6A BR9909328A BR9909328A BR 9909328 A BR9909328 A BR 9909328A BR 9909328 A BR9909328 A BR 9909328A BR 9909328 A BR9909328 A BR 9909328A
Authority
BR
Brazil
Prior art keywords
mflint
flint
opg3
mature
tnf receptor
Prior art date
Application number
BR9909328-6A
Other languages
English (en)
Inventor
Thomas Frank Bumol
Shenshen Dou
Andrew Lawrence Glasebrook
Kenneth Elliot Gould
John Edward Hale
Josef Georg Heuer
Kwan Yuk Hui
Alexei Kharitonenkov
Jacques Mizrahi
Songking Na
Timothy Wayne Noblitt
Charles Arthur Reidy
Ho Yeong Song
Jian Wang
Xiying Wu
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9909328A publication Critical patent/BR9909328A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"APLICAçõES TERAPêUTICAS DE POLIPEPTìDEOS FLINT MADUROS (mFLINT) OU OPG3, UM MEMBRO DA SUPER-FAMìLIA DOS RECEPTORES PARA TNF"<D>. A proteína FLINT madura (mFLINT) se liga ao FasL e à LIGHT, e impede a interação entre FasL-Fas. O mFLINT inibe a atividade apoptótica e pró-inflamatória mediada por FasL-Fas, e é útil no tratamento de distúrbios associados com a apoptose anormal e a inflamação. A invenção proporciona as seq³ências de aminoácidos e de nucleotídeos de FLINT e do FLINT maduro. é divulgada a preparação e a caracterização de animais transgênicos, que expressam o FLINT. As composições terapêuticas e os métodos de tratamento utilizando o mFLINT são também proporcionados.
BR9909328-6A 1998-03-30 1999-03-30 Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf BR9909328A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7985698P 1998-03-30 1998-03-30
US8607498P 1998-05-20 1998-05-20
US9964398P 1998-09-09 1998-09-09
US11257798P 1998-12-17 1998-12-17
US11270398P 1998-12-18 1998-12-18
US11293398P 1998-12-18 1998-12-18
US11340798P 1998-12-22 1998-12-22
PCT/US1999/006797 WO1999050413A2 (en) 1998-03-30 1999-03-30 THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY

Publications (1)

Publication Number Publication Date
BR9909328A true BR9909328A (pt) 2000-12-12

Family

ID=27568394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909328-6A BR9909328A (pt) 1998-03-30 1999-03-30 Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf

Country Status (16)

Country Link
US (1) US20040167074A1 (pt)
JP (1) JP2002512006A (pt)
KR (1) KR20010042364A (pt)
CN (1) CN1303429A (pt)
AU (1) AU3369199A (pt)
BR (1) BR9909328A (pt)
CA (1) CA2324517A1 (pt)
CZ (1) CZ20003433A3 (pt)
EA (1) EA200001004A1 (pt)
HU (1) HUP0102067A2 (pt)
ID (1) ID27820A (pt)
IL (1) IL138626A0 (pt)
NO (1) NO20004873L (pt)
PL (1) PL343847A1 (pt)
TR (1) TR200002824T2 (pt)
WO (1) WO1999050413A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007659B1 (en) 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
EP1140138A2 (en) * 1998-12-22 2001-10-10 Eli Lilly And Company Therapeutic applications of flint polypeptides
WO2000058466A2 (en) * 1999-03-30 2000-10-05 Eli Lilly And Company Protease resistant flint analogs
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
EP1210435A1 (en) 1999-08-04 2002-06-05 Amgen Inc. Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
AU7053000A (en) * 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
EP1225908A2 (en) * 1999-10-20 2002-07-31 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
EP1322667A4 (en) * 2000-08-25 2004-08-18 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS 6-ALPHA AND 6-BETA
WO2002066050A1 (en) * 2001-02-23 2002-08-29 Takeda Chemical Industries, Ltd. Casoase 3 inhibitors
EP1606319A2 (en) 2003-03-26 2005-12-21 Apogenix GmbH Treatment of viral infections
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102671186B (zh) * 2011-09-19 2014-08-06 上海市肿瘤研究所 促造血的药物组合物及其应用
AU2013291981B2 (en) 2012-07-18 2017-05-04 Apogenix Ag Inhibitors of the CD95 signaling pathway for treatment of MDS
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
US10874721B2 (en) 2015-12-18 2020-12-29 Talengen International Limited Method for preventing and treating cervical erosion
EP3391896B1 (en) 2015-12-18 2024-04-10 Talengen International Limited Plasminogen for use in treating treating radiation and chemical damage
JP7760374B2 (ja) 2019-03-29 2025-10-27 ターンストーン バイオロジクス コーポレイション Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
JP2023504042A (ja) 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー 調節物質を使用した腫瘍反応性ｔ細胞組成物の生成方法
EP4110799B1 (en) 2020-02-27 2024-11-06 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007659B1 (en) * 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6 alpha & 6 beta
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
JP2001512667A (ja) * 1997-08-06 2001-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトオーファンレセプターｎｔｒ−１
IL134578A0 (en) * 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2

Also Published As

Publication number Publication date
US20040167074A1 (en) 2004-08-26
NO20004873L (no) 2000-11-24
WO1999050413A3 (en) 1999-12-02
HUP0102067A2 (hu) 2001-10-28
JP2002512006A (ja) 2002-04-23
IL138626A0 (en) 2001-10-31
CN1303429A (zh) 2001-07-11
AU3369199A (en) 1999-10-18
PL343847A1 (en) 2001-09-10
ID27820A (id) 2001-04-26
TR200002824T2 (tr) 2000-12-21
EA200001004A1 (ru) 2001-06-25
CA2324517A1 (en) 1999-10-07
KR20010042364A (ko) 2001-05-25
NO20004873D0 (no) 2000-09-28
CZ20003433A3 (cs) 2001-10-17
WO1999050413A2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
BR9909328A (pt) Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf
Buchan et al. A new model of temporary focal neocortical ischemia in the rat.
KR100574387B1 (ko) 포유류 시토카인 유사 폴리펩티드-10
WO1996009323A1 (en) Il-1 receptor antagonists with enhanced inhibitory activity
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
ES2374971T3 (es) Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
NO993979D0 (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer&#39;s sykdom og sammensetning derfor
BR9804437A (pt) Compostos para a osteoporose
DK0698108T4 (da) Adenovirale vektorer af animalsk oprindelse og deres anvendelse ved genterapi
BR9710362A (pt) Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
BR0001291A (pt) Desfolhante
BR9913955A (pt) Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
BRPI9910024B8 (pt) uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal
BR9712466A (pt) Aplicação de adamantanaminas ou compostos de estrutura análogo para combater o vìrus da doença de borna e para a profilaxia e tratamento de doenças emocionais e outras perturbaçoes ligadas com infecçoes do vìrus bd homem e animal
US20040077543A1 (en) Treatment using neublastin polypeptides
KR102075881B1 (ko) 이질통, 통각과민증, 자발통 및 환상통의 치료
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
DK1012286T3 (da) Allelvariant af humant STAT3
O'connell Role of Fas–FasL in inflammatory diseases
WO2000037094A3 (en) Therapeutic applications of flint polypeptides
IL154777A0 (en) Il-6 receptor/il-6 chimera in huntington&#39;s disease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]